Literature DB >> 8783439

A functional decline model for prevalent cohort data.

X Liu1, W Y Tsai, Y Stern.   

Abstract

Longitudinal designs are often used for studying the natural history of diseases. Data sets typically consist of short series of repeated measures on prevalent cases. We propose a growth model approach to the analysis of follow-up data to describe functional decline and associated risk factors in disease progression. We illustrate the model with an application to longitudinal data that describe the time-evolution of cognitive decline in a cohort of patients with Alzheimer's disease.

Entities:  

Mesh:

Year:  1996        PMID: 8783439     DOI: 10.1002/(SICI)1097-0258(19960530)15:10<1023::AID-SIM212>3.0.CO;2-7

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Authors:  Mahesh N Samtani; Nandini Raghavan; Yingqi Shi; Gerald Novak; Michael Farnum; Victor Lobanov; Tim Schultz; Eric Yang; Allitia DiBernardo; Vaibhav A Narayan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  Jump, Hop, or Skip: Modeling Practice Effects in Studies of Determinants of Cognitive Change in Older Adults.

Authors:  Alexandre Vivot; Melinda C Power; M Maria Glymour; Elizabeth R Mayeda; Andreana Benitez; Avron Spiro; Jennifer J Manly; Cécile Proust-Lima; Carole Dufouil; Alden L Gross
Journal:  Am J Epidemiol       Date:  2016-01-28       Impact factor: 4.897

Review 3.  Modeling the time-course of Alzheimer dementia.

Authors:  J W Ashford; F A Schmitt
Journal:  Curr Psychiatry Rep       Date:  2001-02       Impact factor: 5.285

4.  Education and rates of cognitive decline in incident Alzheimer's disease.

Authors:  N Scarmeas; S M Albert; J J Manly; Y Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

5.  Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.

Authors:  Carina Wattmo; Elisabet Londos; Lennart Minthon
Journal:  BMC Neurol       Date:  2014-09-10       Impact factor: 2.474

6.  Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.

Authors:  Carina Wattmo; Lennart Minthon; Åsa K Wallin
Journal:  Alzheimers Res Ther       Date:  2016-02-17       Impact factor: 6.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.